In CML, clinical investigation is now focusing on how to best identify, based on the entity of BCR-ABL1 transcript reduction, patients who would really benefit from an early switch, how to increase TFR rates, and how to best select TFR candidates. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.